Asked by: Clive Jones (Liberal Democrat - Wokingham)
Question to the HM Treasury:
To ask the Chancellor of the Exchequer, how many individuals with liabilities relating to Loan Charge schemes have a) been offered an opportunity to settle those liabilities , b) have accepted an invitation to settle those liabilities, and c) have settled those liabilities in full since the publication of the Independent Loan Charge Review 2025.
Answered by Dan Tomlinson - Exchequer Secretary (HM Treasury)
I refer the Hon. Member to the answer I gave on 27 April 2026 to UIN 128634.
Asked by: Clive Jones (Liberal Democrat - Wokingham)
Question to the Ministry of Defence:
To ask the Secretary of State for Defence, what his planned timetable is for procuring replacement aircraft for the Hawk T1 Trainer to be used by the Royal Air Force Aerobatic Team.
Answered by Luke Pollard - Minister of State (Ministry of Defence)
Spending decisions on future capabilities will be published as part of the Defence Investment Plan.
Asked by: Clive Jones (Liberal Democrat - Wokingham)
Question to the Ministry of Housing, Communities and Local Government:
To ask the Secretary of State for Housing, Communities and Local Government, what assessment his Department made of the potential impact of the Renters’ Rights Act 2026 on tenants with fixed-term tenancy agreements entered into before the Act’s commencement where such agreements contained no (a) break clause and (b) requirement to give notice at the end of the fixed term, prior to the introduction of that Act to Parliament.
Answered by Matthew Pennycook - Minister of State (Housing, Communities and Local Government)
From 1 May 2026, the new tenancy system provided for by the Renters’ Rights Act applies to all private tenancies.
As such, all tenancies are now periodic and it will no longer be possible to agree a fixed rental term or create a tenancy with an end date or break clause, and any existing terms of these types no longer apply.
My Department engaged extensively with stakeholders from across the sector when developing the reforms in question and an Impact Assessment of the legislation was published.
Asked by: Clive Jones (Liberal Democrat - Wokingham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the withdrawal of hydrocortisone sodium phosphate liquid solution from the medicine market on to patients with adrenal insufficiency.
Answered by Preet Kaur Gill - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is aware of the discontinuation of hydrocortisone sodium phosphate 100mg/1ml solution for injection and we continue to work with industry to find a longer-term solution.
Hydrocortisone sodium succinate 100mg powder remains available for patients. We have issued comprehensive management guidance to healthcare professionals on how to manage patients while supply is disrupted. The guidance highlighted the differences between the two hydrocortisone injections. It also included resources for patients and healthcare professionals on how to administer the alternative hydrocortisone injection.
We also understand that the Addison’s Disease Self Help Group have also published information on this discontinuation to keep patients informed along with resources for patients on how to administer the alternative hydrocortisone.
Asked by: Clive Jones (Liberal Democrat - Wokingham)
Question to the HM Treasury:
To ask the Chancellor of the Exchequer, when she plans to respond to correspondence from the hon. Member for Wokingham transferred to her Department on 24 November 2025, reference MC2025/24514.
Answered by Dan Tomlinson - Exchequer Secretary (HM Treasury)
A response has been sent to the hon. Member for Wokingham.
Asked by: Clive Jones (Liberal Democrat - Wokingham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference his Department's press release entitled NHS patients to get quicker tests and scans closer to home, published on 13 April 2026, whether teenagers and young adults will have access to diagnostic services at new and expanded Community Diagnostic Centres; and what steps his Department is taking to ensure that diagnostic pathways at these Centres are appropriate for patients aged 13–25.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department is committed to transforming diagnostic services and will support the National Health Service to increase diagnostic capacity to bring down the size of the list and reduce waiting times. The Department also recognises that teenagers and young adults require age-appropriate care, regarding diagnosis, treatment and wider support.
In April 2026, the Department announced its plan to open four new community diagnostic centres during 2026/27. The Department also announced a further 32 centres, which will be expanded and improved with new scanning equipment, outpatient clinic space and testing facilities. The 36 centres, backed by a £237 million Government investment, will significantly boost NHS diagnostic capacity and deliver more care in local communities, including for teenagers and young adults.
Asked by: Clive Jones (Liberal Democrat - Wokingham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to page 74 of his Department's document entitled National Cancer Plan for England, published on 4 February 2026, what progress he has made on implementing action 4 in the Rare and less common cancers section; whether his Department has a timeline to introduce the regular publication of data on the occurrence of the emergency diagnoses of non‑stageable cancers, including blood and brain cancers; and what assessment he has made of the potential merits of including such data into early diagnosis performance metrics.
Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Cancer Plan for England sets out a comprehensive ten-year strategy to transform cancer outcomes across the country. Rare and Less Common Cancers have been prioritised through the National Cancer Plan, to drive forward progress for cancers that have previously been neglected.
To meet its obligations for rare cancers, the Government will appoint a new national clinical lead for rare cancers. This national clinical lead will have a clear mandate to speak up for rare cancers, and to provide clinical advice and support for the delivery of the actions in the plan.
Brain and some blood cancers such as leukaemia cannot be staged in the same way as other cancers and are therefore not included in current early‑diagnosis measures. However, the Plan commits to publishing regular data on the number of these cancers diagnosed in emergency settings, as a proxy for late or ineffective diagnosis. Moreover, adding this to the basket of early diagnosis metrics we prioritise will help incentivise systems and providers to focus on earlier diagnosis of blood and brain cancers. This will happen across the lifetime of the plan.
Across the life of the National Cancer Plan, Ministers will publish an annual summary of progress, along with a more in-depth report after three years to assess where the plan may need updating and refreshing.
Asked by: Clive Jones (Liberal Democrat - Wokingham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to action 9 on page 76 of his Department's document entitled National Cancer Plan for England, published on 4 February 2026, what progress he has made on assessing novel procurement routes for diagnostics and treatments for rare cancers, including brain tumours; and what steps his Department is taking to ensure timely adoption and rollout of approved diagnostic innovations.
Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to improving outcomes for people with rare and less common cancers, including brain tumours, and to ensuring that patients benefit from effective innovations as quickly and safely as possible.
The Department is working with NHS England to consider how procurement approaches can better support earlier access to diagnostics and treatments for rare cancers, including for brain tumours. The plan sets out that we will explore new procurement routes in 2026 and we will publish an annual report on progress against the commitments in the National Cancer Plan.
To support timely adoption and rollout of approved diagnostic innovations, NHS England is strengthening cancer pathways and making greater use of digital tools to identify bottlenecks and delays. This includes expanding the use of the Federated Data Platform to all trusts to support clinicians and operational teams to consolidate multiple frontline operational systems into a single view, facilitating more effective and efficient clinical and operational decisions.
The Department is also supporting the deployment of diagnostic innovations through national investment, including focusing the £21 million AI Diagnostic Fund on the deployment of technologies in key, high-demand areas such as chest X-Ray and chest CT scans to enable faster diagnosis and treatment of lung cancer in over half of acute trusts in England.
NHS England will continue to work with Regions and Cancer Alliances to support providers to adopt effective innovations and to improve pathway performance, including targeted support for challenged trusts and pathways.
Asked by: Clive Jones (Liberal Democrat - Wokingham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to page 28 of his Department's document entitled National Cancer Plan for England, published on 4 February 2026, what progress he has made on the development and implementation of multi‑cancer early detection tests; and what assessment his Department has made of the potential merits of evaluating and integrating blood‑based biomarker tests and other non‑invasive diagnostic tools for earlier detection of brain tumours.
Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department will continue to implement the actions set out in the National Cancer Plan, including supporting the development and adoption of multi-cancer early detection tests and other non-invasive diagnostic tools.
Whilst the 10-Year Health Plan anticipated a breakthrough within the next five years, any new screening test must be subject to review by the UK National Screening Committee, to prove safety, efficacy and value before it can become part of a national screening program. We will prioritise further efforts to research and evaluate effective diagnostic tools and tests for rare cancers, including brain cancer, using multi-cancer early detection tests and other non-invasive diagnostic tests.
Asked by: Clive Jones (Liberal Democrat - Wokingham)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, when the correspondence sent on 22nd October 2025 by the Hon. Member for Wokingham, reference number MC2025-00013812, will receive a response.
Answered by Kanishka Narayan - Parliamentary Under Secretary of State (Department for Science, Innovation and Technology)
The Department apologises for the significant delay in responding to the hon. Member’s correspondence on this occasion. I provided a full response on 24 April 2026.